CEO Roundtable Panelist

Raymond De Vré

CEO, PolyPeptide Group

ABSTRACT

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) with around 1’200 employees, focusing on peptides and oligonucleotides. The Group’s mission is to help customers secure regulatory approvals and to successfully launch and commercialize their products. Dating back to 1952, PolyPeptide today has a global footprint of six GMP-certified facilities in Europe, the U.S. and India with a leading market position in outsourced peptide manufacturing. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

BIO

Raymond De Vré
Chief Executive Officer

Nationality: Belgian
Year of birth: 1968

Professional background
Functions at PolyPeptide
• Chief Executive Officer (since 2021)
• Chairman / Director of several PolyPeptide subsidiaries (since 2021)

Outside mandates at listed / non-listed companies or non-profit organizations
• None
Former outside activities and functions
• Senior Vice President, Head of Biologics and member of the Management Committee, Dr. Reddy's Laboratories, Switzerland (2018–2021)
• Senior Vice President Global Business Operations and Strategy, Biologics, Dr. Reddy's Laboratories, Switzerland (2017–2018)
• Vice President Commercial, Biologics, Dr. Reddy's Laboratories, Switzerland (2012–2017)
• Partner, McKinsey & Company, Switzerland (2004–2011)
• Consultant, McKinsey & Company, Belgium / USA / Switzerland (1996–2003)

Education
• PhD in Applied Physics, Stanford University, USA (1996)
• Master's degree in Applied Physics, Stanford University, USA (1992)
• Master’s degree as Ingénieur Civil Physicien, École Polytechnique, Université Libre de Bruxelles, Belgium (1990)